Show simple item record

dc.contributor.authorChew, HY
dc.contributor.authorChan, V
dc.contributor.authorSimpson, F
dc.contributor.authorDolcetti, R
dc.date.accessioned2020-12-09T22:42:33Z
dc.date.available2020-12-09T22:42:33Z
dc.date.issued2020-11-01
dc.identifierpii: cancers12113392
dc.identifier.citationChew, H. Y., Chan, V., Simpson, F. & Dolcetti, R. (2020). Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?. CANCERS, 12 (11), https://doi.org/10.3390/cancers12113392.
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/11343/253048
dc.description.abstractSarcomas are a rare type of a heterogeneous group of tumours arising from mesenchymal cells that form connective tissues. Surgery is the most common treatment for these tumours, but additional neoadjuvant or adjuvant chemotherapy or radiation therapies may be necessary. Unfortunately, a significant proportion of patients treated with conventional therapies will develop metastatic disease that is resistant to therapies. Currently, there is an urgent need to develop more effective and durable therapies for the treatment of sarcomas. In recent years immunotherapies have revolutionised the treatment of a variety of cancers by restoring patient anti-tumour immune responses or through the adoptive infusion of immune effectors able to kill and eliminate malignant cells. The clinicopathologic and genetic heterogeneity of sarcomas, together with the generally low burden of somatic mutations potentially generating neoantigens, are currently limited to broad application of immunotherapy for patients with sarcomas. Nevertheless, a better understanding of the microenvironmental factors hampering the efficacy of immunotherapy and the identification of new and suitable therapeutic targets may help to overcome current limitations. Moreover, the recent advances in the development of immunotherapies based on the direct exploitation or targeting of T cells and/or NK cells may offer new opportunities to improve the treatment of sarcomas, particularly those showing recurrence or resistance to standard of care treatments.
dc.languageEnglish
dc.publisherMDPI
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleWill Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?
dc.typeJournal Article
dc.identifier.doi10.3390/cancers12113392
melbourne.affiliation.departmentMicrobiology and Immunology
melbourne.source.titleCancers
melbourne.source.volume12
melbourne.source.issue11
melbourne.source.pages3392-3392
dc.rights.licenseCC BY
melbourne.elementsid1481312
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697818
melbourne.contributor.authorDolcetti, Riccardo
dc.identifier.eissn2072-6694
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record